TP53 and neoplasm: Subsequently, the TransPORTEC and ProMisE research groups showed that molecular classification could be assessed in clinical pathology with surrogate markers, yielding robust prognostic differences: tumours with a pathogenic POLE mutation (POLEmut) have an excellent prognosis, mismatch repair-deficient (MMRd) tumours have an intermediate prognosis, tumours with no specific molecular profile (NSMP) have a grade-dependent and stage-dependent intermediate prognosis, and p53-abnormal (p53abn) tumours have a poor prognosis.